<DOC>
	<DOCNO>NCT01220869</DOCNO>
	<brief_summary>A phase III trial investigate efficacy safety degarelix one-month depot Taiwanese patient prostate cancer .</brief_summary>
	<brief_title>A Study Degarelix Taiwanese Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>20 year old Has histological confirm prostate cancer Has screening serum testosterone 1.5 ng/mL Has Eastern Cooperative Oncology Group ( ECOG ) score ≤ 2 Has screen PSA value ≥2 ng/mL Has life expectancy least 168 day Current previous hormone therapy Is currently treat 5αreductase inhibitor Has history severe untreated asthma , anaphylactic reaction , severe urticaria and/or angioedema Is consider candidate curative therapy , i.e radical prostatectomy radiotherapy Has cancer within last five year except prostate cancer surgically remove basal squamous cell carcinoma skin . Has clinically significant disorder ( prostate cancer ) condition , include alcohol drug abuse , may interfere trial participation may affect conclusion trial judge investigator Has receive investigational drug within last 28 day precede Screening Visit longer consider possibly influence outcome current trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>